Latest Asx Listing Rules News

G50 Corp has raised A$26.25 million through a well-supported institutional placement, with Hancock Prospecting taking a significant stake. The funds will accelerate drilling and metallurgical work at its Golconda and White Caps projects in the United States.

Golden Dragon Mining has raised A$2.2 million through a strategic placement to Chengtun Gold, a subsidiary of Shanghai-listed Chengtun Mining Group, at a near 18% premium. The deal grants Chengtun a board seat and aims to accelerate exploration at the Cue Gold Project.

Greenvale Energy has secured $3.25 million through a placement to fast-track uranium exploration at its Thunderball Project in the Northern Territory, while also advancing its Pine Creek acquisition.

WA Gold has delivered a robust scoping study for its Abercromby Gold Project, forecasting strong cashflows and low capital costs, while ramping up drilling at both Abercromby and Bullabulling projects with assay results imminent.

Tali Resources has kicked off a broad aircore drilling campaign at its West Arunta Project, backed by a $3 million placement and a $270,000 government grant to fund further prospect testing.

European Lithium (ASX: EUR) has obtained a crucial ASX waiver allowing it to cancel unlisted options and performance rights without shareholder approval, smoothing the path for its acquisition by NASDAQ-listed Critical Metals Corp (NASDAQ: CRML).

Radiopharm Theranostics (ASX: RAD) has requested an immediate voluntary suspension of its shares pending a material capital raising announcement expected before markets open on 27 July 2026.

Stelar Metals confirms recent share price and volume spikes are linked to disclosed exploration milestones at its Hill of Leaders Tungsten Project, with no undisclosed information influencing trading.

OZZ Resources moves closer to acquiring Sulphide Minerals and regaining ASX listing with a $5 million capital raise, while navigating legal challenges on key tenements.

Tissue Repair Limited (ASX: TRP) has applied to delist from the ASX, citing limited liquidity and high listing costs. The company plans a shareholder vote and a $1 million off-market buy-back at a premium to recent prices.

Papyrus Australia has tapped related party L39 Capital to lead a capital raise and secured an interest-bearing $200,000 loan from Irwin Biotech, with conversion into shares and options pending shareholder approval.

Cambium Bio has raised just over A$1 million through a strategic placement at a 17% premium, boosting a key shareholder’s stake as it advances its pivotal Phase 3 trial for dry eye disease.